This deliverable reports on the external validation of three disease progression models for AD dementia: Handels’ Mini-Mental State Examination (MMSE) model, Novartis’ preclinical model, and Eli Lilly’s institutionalization model. For each of these models, data sources for external validation were sought. A validation pipeline was developed to standardize the analyses across multiple data sources, reduce the workload of database custodians, and increase transparency and repeatability. The pipeline consists of the following steps: documentation of the model development and validation steps, specification of a statistical analysis plan, extraction and standardization of the data, and generation of the validation results.